LiBBY Dementia Agitation Trial: Promising 2026 Findings and Important Limits

The LiBBY trial tested a THC/CBD medicine — not lithium — for agitation in late-stage dementia, and its 2026 results are genuinely promising: agitation fell significantly more on the active drug than on placebo. But the same data carry a serious warning, with more serious infections and more deaths in the treated group, according to the AAIC 2026 press release. LiBBY stands for "Life's End Benefits of cannaBidiol and tetrahYdrocannabinol." Despite a name that reads like a lithium study, the intervention is cannabis-derived, and the findings are early top-line data, not a finished, published result.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What LiBBY actually tested
How strong were the benefits?
The safety signal you should not overlook
Who ran it, and how finished is it?
What this means for a family right now
Frequently Asked Questions

What LiBBY actually tested

LiBBY was a Phase 2 trial — an early study designed to gauge whether a treatment works and is safe enough to study further. It was multicenter, randomized, double-blind, and placebo-controlled, the strongest design short of a large confirmatory trial. The study enrolled 120 participants across 10 U.S. sites, with a mean age of 80.

As NeurologyLive reports, 55% were female and 45% were Hispanic or Latino — an unusually diverse sample for a dementia trial. Every participant had Alzheimer's or another dementia, clinically significant agitation, and was eligible for hospice. The drug, called T2:C100, was taken twice daily. Participants started at a half dose (2 mg THC / 100 mg CBD) for the first week, then moved to a full dose (4 mg THC / 200 mg CBD) from weeks 2 through 12.

How strong were the benefits?

The main measure was agitation on the Cohen-Mansfield Agitation Inventory, a standard checklist rating behaviors like pacing, restlessness, and aggression. At two weeks, the active drug beat placebo by a statistically significant 6.27 points, meaning the difference is unlikely to be chance. By week 12, roughly 9 in 10 participants showed overall symptom improvement, according to the EurekAlert summary of AAIC 2026.

For families watching a loved one distressed and agitated near the end of life, a real reduction in those symptoms matters. Keep two caveats in view. The improvement figure covers overall symptoms, not agitation alone, and there was no long-term follow-up beyond the 12-week window.

The safety signal you should not overlook

The benefits came with a genuine cost. Overall rates of side effects were similar between groups, but serious adverse events were roughly twice as high on the active drug — 23.3% versus 11.9%. The gap was driven largely by serious infections, at 11.7% on the drug versus 1.7% on placebo.

Deaths were also higher: 13.1% versus 5.1%, per NeurologyLive. These numbers deserve caution rather than panic. Everyone in the trial was hospice-eligible, so some deaths were expected regardless of treatment. Still, the size of the difference is why researchers are describing the results as promising but not settled.

Who ran it, and how finished is it?

The trial was primarily funded by the National Institute on Aging, part of the NIH, and led by Jacobo Mintzer, M.D., of the Ralph H. Johnson VA Healthcare System and the Medical University of South Carolina. That is independent, government-backed research rather than an industry marketing study.

The findings are preliminary top-line data presented at the AAIC 2026 conference in London. As the Alzheimer's Association notes, the full trial has not yet been peer-reviewed, published, or indexed in PubMed, and no publication date has been announced. Treat the results as an early signal. Numbers presented at conferences sometimes shift once the complete data set is reviewed and published.

What this means for a family right now

This drug is not FDA-approved for dementia agitation, and nothing here changes what is available today. The trial studied late-stage, hospice-eligible patients, so its results may not apply to someone in early or moderate dementia. If agitation is a problem for someone you care for, here is a practical way to use this news:.

Do not seek out THC/CBD products on your own based on this trial — the safety signal was real, and store products are not the tested formulation or dose.
Ask the treating physician or hospice team whether cannabinoid options are appropriate for your specific situation.
Rule out treatable triggers first: pain, infection, constipation, and medication side effects are common, reversible causes of agitation.
If the person is in late-stage or hospice care, discuss the risk-benefit tradeoff directly, given the higher infection and mortality rates seen in the trial.

Frequently Asked Questions

Is LiBBY a lithium trial?

No. Despite the name, LiBBY tested a THC/CBD cannabinoid drug for dementia agitation, not lithium.

Can I get this treatment now?

No. T2:C100 is not FDA-approved for dementia agitation, and the results are preliminary data not yet peer-reviewed or published.

Does this apply to early-stage dementia?

The trial only studied late-stage, hospice-eligible patients, so its benefits and its infection and mortality risks may not carry over to earlier stages.